Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.

Fiche du document

Auteurs
Date

9 novembre 2017

Type de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1161/JAHA.117.006537

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/29122809

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2047-9980

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_6ADD455560971

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/

Mots-clés 0

Acute Coronary Syndrome/blood; Acute Coronary Syndrome/drug therapy; Anticholesteremic Agents/administration & dosage; Apoptosis; Cardiology; Cholesterol, LDL/blood; Dose-Response Relationship, Drug; Eligibility Determination/methods; Europe; Ezetimibe/administration & dosage; Female; Follow-Up Studies; Humans; Male; Middle Aged; Practice Guidelines as Topic; Proprotein Convertase 9/antagonists & inhibitors; Prospective Studies; Societies, Medical; Time Factors; Treatment Outcome; United States; PCSK9; lipids; secondary prevention

Sujets proches En

Cholesterin

Citer ce document

B. Gencer et al., « Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. », Serveur académique Lausannois, ID : 10.1161/JAHA.117.006537

Métriques

Partage / Export

Résumé 0

The American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) have recently published recommendations for the use of proprotein convertase subtilisin/kexin-9 (PCSK9) inhibitors in situations of very high risk. We aim to assess in the real world the suitability of PCSK9 inhibitors for acute coronary syndromes. We analyzed a prospective Swiss cohort of 2023 patients hospitalized for acute coronary syndromes between 2009 and 2014 with available data for low-density lipoprotein cholesterol and lipid-lowering therapy at 1 year. Clinical familial hypercholesterolemia was defined using the Dutch Lipid Clinic Network algorithm as unlikely, possible, probable, or definite. We simulated a fixed relative reduction of 24% in low-density lipoprotein cholesterol levels at 1 year in all patients not treated with ezetimibe, irrespective of the low-density lipoprotein cholesterol levels and statin regimen. At 1 year, 94.3% of patients were treated with statin, 5.8% with ezetimibe, and 35.8% of patients had on-target low-density lipoprotein cholesterol levels (

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en